Medexus Pharmace Stock Price, News & Analysis

Medexus Pharmaceuticals announced its participation in the 35th Annual Roth Conference scheduled for March 12-14, 2023, in Dana Point, California. The company's presentation, featuring CEO Ken d’Entremont and CFO Marcel Konrad, is set for March 14 at 1:00 PM PT (4:00 PM ET). Attendees can join the live and recorded webcast on the company’s investor relations page. Medexus specializes in innovative treatments for rare diseases, focusing on hematology, auto-immune diseases, and allergies.

For more details and registration, visit this link.

Medexus Pharmaceuticals (OTCQX: MEDXF) announced strong fiscal Q3 2023 results, with record revenue of $28.7 million, marking a 35% year-over-year increase and a 4% quarter-over-quarter increase. This growth is attributed to net sales across its product portfolio, including full recognition of Gleolan sales in the U.S. Adjusted EBITDA reached $5.2 million, up $3.3 million year-over-year. While operating profit improved to $2.9 million, the company reported a net loss of $(1.5) million. Cash and cash equivalents stood at $9.3 million. Management anticipates ongoing investments in working capital and is exploring options to manage near-term liabilities.

Medexus Pharmaceuticals has appointed Harmony P. Garges, MD MPH, and Menassie Taddese, MBA, to its board of directors, effective February 6, 2023. These additions aim to enhance the board's medical and financial expertise, particularly in the United States. Dr. Garges, with 18 years in pharmaceutical leadership and experience as Chief Medical Officer at ViiV Healthcare, will contribute insights into medical affairs and regulatory matters. Mr. Taddese brings over 26 years of biopharmaceutical experience, focusing on management and finance. Their appointments reflect Medexus's commitment to strong leadership as it seeks growth opportunities.

Medexus Pharmaceuticals (OTCQX: MEDXF) announces a partnership with the Quebec government for public reimbursement of Cuvposa (glycopyrrolate oral solution) effective February 1, 2023. This medication, aimed at reducing chronic severe drooling in pediatric patients aged 3 to 18 with neurological conditions like cerebral palsy, will now be accessible to a broader range of patients. Notably, the incidence of cerebral palsy in Canada is projected to rise, increasing the need for effective treatments. Medexus expresses commitment to improving quality of life for affected children and their families through enhanced treatment access.

Medexus Pharmaceuticals (OTCQX: MEDXF) will host a conference call on February 9, 2023, at 8:00 am ET to discuss its third fiscal quarter results for the period ending December 31, 2022. The financial statements and MD&A will be filed after market close on February 8, 2023. Participants can join the call via toll-free numbers or an international dialing option. A live webcast will be available, with a replay accessible for a week following the call. Medexus focuses on innovative therapeutic solutions for rare diseases, including products like IXINITY® and Rasuvo® for hematology and auto-immune diseases.

Medexus Pharmaceuticals announced preliminary revenue estimates for fiscal Q3 2023, projecting total revenue between $28.5 million and $29.0 million, marking a record quarter with a 34% year-over-year increase. Key revenue drivers include strong sales of IXINITY, Rasuvo, Rupall, and Gleolan. However, progress on treosulfan is delayed, as medac must gather additional data for the FDA, potentially extending the NDA resubmission timeline by up to a year. Medexus aims to maintain momentum in its current product portfolio while seeking new opportunities.

Medexus Pharmaceuticals (MEDXF) reported record total revenue of $27.7 million for Q2 fiscal 2023, reflecting a 55% year-over-year increase and a 20% quarter-over-quarter increase, marking its strongest quarter ever. Key drivers included increased sales from IXINITY and Rupall, alongside full recognition of Gleolan's U.S. revenues. Adjusted EBITDA rose to $4.2 million. Despite a net loss of $(2.7 million), adjusted net loss improved to $(2.8 million). The company ended the quarter with $9.6 million in cash and plans to enhance its balance sheet.

Medexus Pharmaceuticals (OTCQX: MEDXF) will host a conference call on November 9, 2022, at 8:00 am ET to discuss its second-quarter results for the period ending September 30, 2022. The financial statements and MD&A will be filed after the market closes on November 8, 2022. Dial-in numbers are provided for Canadian, U.S., and international callers. A replay will be available post-call until November 16, 2022. Medexus focuses on rare disease treatments, with products like Rasuvo™ and IXINITY® among its portfolio, aiming for continued growth in innovative therapies.

Medexus Pharmaceuticals has announced preliminary revenue estimates for fiscal Q2 2023, expecting total revenue to exceed US$27.0 million, marking a record high. This represents at least a 51% increase from US$17.9 million in Q2 2022, and a 17% increase from US$23.0 million in Q1 2023. Key product drivers include positive sales trends for IXINITY, strong performance in Rasuvo and Rupall, and continued growth in Gleolan. The company emphasizes ongoing operational efficiencies and bolstered liquidity through a recent partnership extension.